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Open acca b s t r a c t
Two simple and reliably accessible intermediates, N-carboxypentyl- and N-aminohexyl-1-deoxy-D-
galactonojirimycin were employed for the synthesis of a set of terminally N-dansyl substituted deriv-
atives. Reaction of the terminal carboxylic acid of N-carboxypentyl-1-deoxy-D-galactonojirimycin with
N-dansyl-1,6-diaminohexane provided the chain-extended ﬂuorescent derivative. Employing bis(6-
dansylaminohexyl)amine, the corresponding branched di-N-dansyl compound was obtained. Partially
protected N-aminohexyl-1-deoxy-D-galactonojirimycin served as intermediate for two additional
chain-extended ﬂuorescent 1-deoxy-D-galactonojirimycin (1-DGJ) derivatives featuring terminal dansyl
groups in the N-alkyl substituent. These new compounds are strong inhibitors of D-galactosidases and
may serve as leads en route to pharmacological chaperones for GM1-gangliosidosis.
 2011 Published by Elsevier Ltd. Open access under CC BY-NC-ND license.1. Introduction
Over the past three decades, iminosugars in the widest sense
and, in particular, iminoalditols as powerful inhibitors have been
valuable tools for the investigation and characterization of glyco-
side hydrolases.1 Due to the vital roles of these enzymes, their
inhibitors exert notable biological activities including anti-viral
and anti-metastatic properties as well as powerful effects on vari-
ous metabolic disorders including type 2 Diabetes and certain
forms of hereditary lysosomal disorders.2–5 This group of over 40
metabolic diseases arises from mutations in speciﬁc genes that
lead to deﬁciencies in enzymes involved in the lysosomal degrada-
tion of glycolipids and glycans.
Recently, these diseases have attracted considerable interest
and considerable efforts have been made to provide novel thera-
peutic compounds which may relieve the various symptoms that
arise from the inability of lysosomal glycosidases to degrade their
respective substrates. These consequently accumulate in the cells
and lead to irreversible damages of nerve tissue, bones as well asx: +43 316 873 8740.
ess under CC BY-NC-ND license.various other organs resulting in painful long term suffering of pa-
tients and their families.
The work of many groups has shown that iminosugars as well
as amine-substituted carbasugars may be suitable therapeutic
agents that function either by inhibiting upstream enzymes and,
thus, reducing the production of metabolites that cannot be de-
graded rapidly enough by the respective enzymemutant (substrate
reduction therapy, SRT) or by helping the folding and transport of
mutant enzymes to the lysosome (chaperone mediated therapy,
CMT). The latter, in particular, would have quite a few attractive
features: it was suggested that sub-inhibitory concentrations of ac-
tive site speciﬁc molecules (pharmacological chaperones) could be
exploited.2 These small molecules bind to and stabilize mutant
proteins such as lysosomal b-glucosidase, b-galactosidase or b-N-
acetylhexosaminidase in their functional folded conformations
and assist their exit from the endoplasmatic reticulum and subse-
quent transport to the lysosome. Mutant proteins that cannot ob-
tain/retain their functional conformation are recognized as
misfolded by the quality control machinery in the endoplasmatic
reticulum and are eventually targeted for degradation.
Recent contributions by various leaders in the ﬁeld seem to sug-
gest that N-substituted iminoalditols and similarly functionalized
structures bind better than their more polar parent compounds
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lipophilic pockets around the enzymes’ active sites.
N-Butyl-1-DNJ (1a) is one of the best studied iminosugars in
this context5 (Fig. 1). Recently, unusual structures such as bicyclic
nojirimycin derivatives 26 and a lipophilic derivative of isofago-
mine, 3,7 have also been found to exert excellent activities. Other
researchers such asWong and his group8 as well as Aerts and Over-
kleeft and their co-workers9 have observed that large, lipophilic N-
alkyl substituents, in particular adamantyl capped spacer arms
(compounds 4), greatly improve the interaction between iminoald-
itol derivatives and the lysosomal b-glucosidase.
For treatment of GM1-gangliosidosis, which is characterized by
deﬁcient activity of lysosomal b-galactosidase, N-modiﬁed deriva-
tives of 1-deoxy-D-galactonojirimycin (5) as well as of 1-deoxynoj-
irimycin (1) have been investigated as candidates for substrate
reduction therapy in a mouse model.10
One of the current benchmark molecules for chaperone medi-
ated therapy (CMT) is NOEV (N-octyl-epi-valieneamine) 6, a
carbasugar.11
These guiding results, in line with our interest in ﬂuorescently
tagged glycosidase inhibitors for diagnostic purposes,12,13 as well
as encouraging biochemical results with one of our dansylated
compounds,14 have led us to prepare a range of N-modiﬁed 1,5-
iminoglucitols from partially protected L-arabino-hexos-5-ulose
(7), amongst them compounds 8, 9 as well as 13 and 15.
2. Results and discussion
Based on previous results with a ﬂuorescent iminoalditol-lysine
hybrid,14 compounds reported here were designed to provide in-
sight into the contribution of simple linear and branched spacer
arms featuring various degrees of lipophilicity and polarity. Three
differently structured amides and one tertiary amine were pre-
pared and their physico-chemical behaviour and biological activi-
ties were investigated.
We have found N-aminohexyl as well as N-carboxypentyl deriv-
atives very versatile and convenient intermediates en route to the
desired inhibitors addressed in this and previous studies.HO
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Figure 1. Glucosidase and galactosidase inhibitors as potential therapeutic principlBased on experimental results in the D-gluco series,15 com-
pounds 8 and 9 were prepared following a reliable route, this time
starting from N-carboxypentyl-1-deoxy-D-galactonojirimycin (5c),
which, in turn, had been accessed by reaction of 3,4-isopropyli-
dene-L-arabino-hexos-5-ulose16 (7) with methyl 6-aminohexano-
ate under reductive amination conditions and subsequent acidic
cleavage of the isopropylidene acetal to give 5b, followed by
saponiﬁcation of the methyl ester with NaOH in water/dioxane
(Scheme 1).
Reaction of intermediate 5c with N-dansyl-1,6-diaminohex-
ane15A (prepared in four simple steps from 6-aminohexanol) under
standard peptide coupling conditions employing O-(benzotriazol-
1-yl)-N,N,N0,N0-tetramethyluronium tetraﬂuoroborate (TBTU) in
Et3N/DMF gave iminoalditol 8 as a yellow-green ﬂuorescent syrup
(Scheme 2). Similarly, compound 9 was prepared by reacting di-
(N-dansyl-6-amino)hexylamine B15 with intermediate 5c (TBTU,
Et3N, DMF).
Starting from known16 N-(6-amino)hexyl-3,4-O-isopropyli-
dene-1-deoxy-D-galactonojirimycin (10), the desired ﬂuorescent
chain extension was introduced in good yield by reaction of mesy-
late C15, to provide partially protected compound 11 (47%, Scheme
3). As a side product, tertiary amine 12 (9%) was obtained and
deprotected to provide di-dansyl substituted iminosugar 13
(quant.). N-Acylation of the secondary amine 11 with octanoic
chloride led to lipophilic intermediate 14 (71%) which upon acid
treatment was converted into inhibitor 15 (quant.; Scheme 4).
In a general screen with three standard galactosidases (Table 1),
compound 8 was found to be a powerful inhibitor of the GH1
b-glucosidase from Agrobacterium sp. (Ki = 0.45 lM; Parent com-
pound 5: Ki = 12 lM) as well as the GH2 Escherichia coli lacZ
b-galactosidase (Ki = 0.27 lM) and inhibited the GH27 a-galactosi-
dase from green coffee beans (GCB) with Ki = 3.4 lM. Compound 9
had a similar inhibitory proﬁle with Ki 0.63 lM (Agrobacterium sp.),
Ki = 0.29 lM (E. coli) and Ki = 2.6 lM (GCB). Compound 13 was bet-
ter by a factor of two with the two b-galactosidases (Ki = 0.23 lM
and 0.12 lM, resp.) and about ﬁvefold more active (Ki = 0.53 lM)
with the a-speciﬁc enzyme. Interestingly, inhibitor 15 showed
impressive b-galactosidase inhibition (Ki 28 nM and 47 nM,N
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Table 1
Ki-values (lM) of compounds with ABG = b-glucosidase/b-galactosidase from Agro-
bacterium sp.; E. coli = b-galactosidase from E. coli, GCB = a-galactosidase from green
coffee beans
Enzyme Compounds
5 8 9 13 15
ABG (Ki) 12 0.45 0.63 0.23 0.028
E. coli (Ki) 12.5 0.27 0.29 0.12 0.047
GCB (Ki) 0.0016 3.4 2.6 0.53 0.02
HLbG (IC50) 69 6.2 0.85 2.7 1.8
HLaG (IC50) 0.27 104 41 81 24
HLbG = human lysosomal b-galactosidase (pH 4.5), HLaG = human lysosomal a-
galactosidase (pH 4.5); IC50 (lM) for compounds with human lysosomal b- as well
as a-galactosidase.
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coffee bean a-galactosidase (Ki 0.20 lM).
With regard to human lysosomal b-galactosidase, compounds 8,
9, 13 and 15 functioned as low micromolar inhibitors (IC50 =
6.2 lM, 0.85 lM, 2.7 lM and 1.8 lM, respectively). In contrast,
compounds 8, 9, 13 and 15 acted as weak inhibitors of lysosomal
a-galactosidase, displaying IC50 more than 50-fold greater relative
to the values obtained for lysosomal b-galactosidase (104 lM,
41 lM, 81 lM and 24 lM, respectively).
Intracellular b-galactosidase and b-N-acetylhexosaminidase
was determined using MU based substrates following lysis of trea-
ted cells. Activity was normalized to DMSO treated cells.
A feline ﬁbroblast line bearing the p.Arg483Pro mutation in b-
galactosidase17 was used to examine the chaperoning efﬁcacy of
each of the four compounds (Fig. 2A and B). Relative to DMSO trea-
ted cells, compounds 8, 9, and 13maximally increased intracellular
b-galactosidase activity 1.7 (258 lM), 1.5 (2.1 lM) and 1.8 (3.0 lM)
fold.With the exception of compound 8, b-galactosidase and b-hex-
osaminidase activity relative to DMSO treated cells declined at con-
centrations between 5 and 20 lM, indicative of inhibitory effects by
compounds 9, 13, and 15 at these levels. Compound 8 was excep-0.1 1 10 100 1000
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Figure 2. (A) Intracellular b-galactosidase following treatment of feline ﬁbroblasts
expressing the b-galactosidase p.Arg483Pro mutation. Fibroblasts were grown in
the presence of escalating dose of compounds 8, 9, 13 and 15 for 5 days. (B) Effects
of compounds on lysosomal N-acetylhexosaminidase.tional in that it had a large range over which it enhanced b-galacto-
sidase activity. This may be due to the fact that it is a slightly
weaker inhibitor and, thus, causes a later onset of inhibitory effects
compared to 9, 13 and 15. No undesired inhibitory effect was ex-
erted on lysosomal N-acetyl-b-hexosaminidase (Fig. 2B).
When human ﬁbroblasts expressing wild type b-galactosidase
were treated overnight with different concentrations of the com-
pounds and subsequently examined using ﬂuorescence microscopy
a punctate staining pattern was observed (Fig. 3). One interpreta-
tion consistent with this staining pattern is that compounds were
found in the lysosome, either due to the hydrophobic nature of
the compounds or by way of their association with b-galactosidase.
These results not only demonstrate the enzyme enhancement efﬁ-
cacy of the compounds but are also suggestive of the utility of these
derivatives as novel intracellular organellar probes of the lysosome.3. Experimental
3.1. General methods
Optical rotations were measured on a Perkin Elmer 341 polar-
imeter at the wavelength of 589 nm and a path length of 10 cm
at 20 C. NMR spectra were recorded on a Varian INOVA 500 oper-
ating at 599.82 MHz (1H), and at 125.894 MHz (13C) or on a Bruker
Ultrashield spectrometer at 300.36 and 75.53 MHz, respectively.
CDCl3 was employed for protected compounds and MeOH-d4 or
D2O for unprotected inhibitors. Chemical shifts are listed in delta
employing residual, non-deuterated solvent as the internal stan-
dard. The signals of the N-dansyl aromatic moieties were found
in the expected regions and are not listed explicitly. MALDI-TOF
Mass Spectrometry was performed on a Micromass TofSpec 2E
Time-of-Flight Mass Spectrometer. Analytical TLC was performed
on precoated aluminum plates Silica Gel 60 F254 (E. Merck
5554), detected with UV light (254 nm), 10% vanillin/sulfuric acid
as well as ceric ammonium molybdate (100 g ammonium molyb-
date/8 g ceric sulfate in 1 L 10% H2SO4) and heated on a hotplate.
Preparative TLC was performed on precoated glass plates Silica
Gel 60 F254, 0.5 mm (E. Merck 5744). For column chromatography
Silica Gel 60 (230–400 mesh, E. Merck 9385) was used.
3.2. Kinetic studies
3.2.1. Agrobacterium sp. b-galactosidase/-glucosidase
The puriﬁcation and assay of Agrobacterium sp. b-galactosi-
dase/-glucosidase was done as described.18 Kinetic studies were
performed at 37 C in pH 7.0 sodium phosphate buffer (50 mM)
containing 0.1% bovine serum albumin, using 7.2  105 mg/mL
enzyme. Approximate values of Ki were determined using a ﬁxed
concentration of substrate, 4-nitrophenyl b-D-glucopyranoside
(0.11 mM = 1.5  Km) and inhibitor concentrations ranging from
0.2 times to 5 times the Ki value ultimately determined. A horizon-
tal line drawn through 1/Vmax in a Dixon plot of this data (1/V vs
[I]) intersects the experimental line at an inhibitor concentration
equal to Ki. Full Ki determinations where required, were per-
formed using the same range of inhibitor concentrations while also
varying substrate (4-nitrophenyl glucoside) concentrations from
approximately 0.015–0.6 mM. Data were analysed by direct ﬁt to
the Michaelis Menten equation describing reaction in the presence
of inhibitors using the program GRAFIT.
3.2.2. E. coli b-galactosidase
Sigma: kinetic studies for E. coli b-galactosidase were performed
at 37 C in pH 7.0 sodium phosphate buffer (50 mM), using sufﬁ-
cient enzyme such less than 10% of the total substrate was con-
verted to product during the observation period of approx 5 min.
Figure 3. Intracellular staining of human ﬁbroblasts with ﬂuorescent compounds 8 (258 lM), 9 (177 lM), 13 (3.4 lM) and 15 (82 lM) (A–D, respectively). Fibroblasts were
treated with the compounds overnight. Fluorescent images were obtained using FITC ﬁlter. All images were exposed using the same settings.
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tion of substrate, 2-nitrophenyl b-D-galactopyranoside (0.15 mM =
1.5  Km) and inhibitor concentrations ranging from 0.2 times to 5
times the Ki value ultimately determined.
3.2.3. Green coffee bean a-galactosidase
Sigma: kinetic studies for green coffee beana-galactosidasewere
performed at 37 C in pH 6.5 sodium phosphate buffer (50 mM),
using sufﬁcient enzyme that less than 10% of the total substrate
was converted to product during the observation period of approx
5 minutes. Approximate values of Ki were determined using a ﬁxed
concentration of substrate, 4-nitrophenyl a-D-galactopyranoside
(0.7 mM = 1.5  Km) and inhibitor concentrations ranging from 0.2
times to 5 times the Ki value ultimately determined.
3.2.4. Human lysosomal a- and b-galactosidase
The inhibitory activity of compounds 8, 9, 13 and 15 was also
evaluated using a lysosomal enzyme enriched conA-fraction from
human placenta as the enzyme source.19 4-Nitrophenyl b-D-galac-
topyranoside (6.3 mM) or 4-nitrophenyl a-D-galactopyranoside
(17 mM) were employed as substrates. Reactions were performed
at 37 C in pH 4.5 citrate phosphate buffer (100 mM) as described
previously.20 IC50 values (lM) were extracted from the enzyme
activity curves in the presence of increasing concentrations of the
inhibitor using non-linear regression as implemented within
Graphpad Prism 5.
3.2.5. Intracellular b-galactosidase activity
GM1 gangliosidosis ﬁbroblasts derived from an affected cat
were treated with escalating doses of compounds 8, 9, 13 and 15
(dissolved in DMSO) for 5 days. Intracellular b-galactosidase activ-
ity was measured using the ﬂuorogenic substrate 4-methylumbel-
liferyl b-D-galactopyranoside as previously described.20
3.2.6. Intracellular staining
Human ﬁbroblasts expressing wild type lysosomal b-galactosi-
dase were treated overnight with increasing doses of compounds8, 9, 13 and 15 (dissolved in DMSO) diluted in alpha-MEM growth
media containing 10% fetal calf serum. Intracellular ﬂuorescence
arising from the compounds was visualized using the FITC ﬁlter
on a Leica microscope with a DFC300F digital camera.
3.3. N-Methoxycarbonylpentyl-1,5-dideoxy-1,5-imino-D-
galactitol (5b)
To a solution of 3,4-isopropylidene-L-arabino-hexos-5-ulose16
(7, 580 mg, 2.46 mmol) in MeOH (30 mL), methyl 6-aminocaproate
(410 mg, 2.82 mmol, 1.15 equiv) and Pd(OH)2 (20%, 100 mg) were
added and the mixture was stirred under an atmosphere of hydro-
gen at ambient pressure for 48 h. The catalyst was removed by ﬁl-
tration and washed with MeOH. To the combined ﬁltrate and
washings, a 5% methanolic solution of HCl (freshly prepared by
addition of acetyl chloride to MeOH) was added and the reaction
was kept at ambient temp for 24 h. The solvent was removed under
reduced pressure and the remaining residue was chromatographed
on silica gel (CHCl3/MeOH/concd NH4OH 30:10:1 v/v/v) to give
known compound 5b (165 mg, 23%) as a colourless syrup. ½a20D
14.3 (c 1.0, MeOH); 1H NMR (500 MHz, MeOH-d4): d = 4.01 (br
s, 1H, H-4), 3.88–3.78 (m, 3H, H-2, H-6a, H-6b), 3.65 (s, 3H,
OMe), 3.29–3.23 (m, 1H, H-3), 3.05 (dd, 1H, J5,6 = 4.3 Hz,
J6,60 = 11.0 Hz, H-1eq), 2.87–2.76 (m, 1H, H-10a), 2.69–2.55 (m, 2H,
H-10b, H-5), 2.34 (t, 2H, J = 7.4 Hz, H-50), 2.25 (m, 1H, H-1ax),
1.69–1.60 (m, 2H), 1.60–1.50 (m, 2H), 1.37–1.35 (m, 2H); 13C
NMR (125 MHz, MeOH-d4): d = 175.8 (C-60), 76.8, 72.0, 68.5, 65.4,
62.1, 57.4 (C-1, C-2, C-3, C-4, C-5, C-6), 53.9 (C-10), 52.0 (OMe),
34.6, 27.9, 25.8, 24.6 (C-20, C-30, C-40, C-50). MS: Calcd for
[C13H25NO6H]: m/z 292.1760 [M+H]+; Found: [M+H]+ 292.1743.
3.4. N-(Dansylamino)hexylaminocarbonylpentyl-1,5-dideoxy-
1,5-imino-D-galactitol (8)
To an aqueous solution (3 mL) of N-methoxycarbonylpentyl-1-
deoxy-D-galactonojirimycin (5b, 150 mg, 0.51 mmol), 0.5 M aque-
ous NaOH (2.0 mL, 1.0 mmol) was added and the mixture was kept
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addition of aqueous HCl (5%) and the solvent was removed under
reduced pressure to give crude 5c. Mono-N-dansyl-1,6-diamino-
hexane15 (A, 200 mg, 0.57 mmol) in dichloromethane (5 mL) was
added to this crude 5c and the solvent was again removed under
reduced pressure. The residue was dissolved in DMF (4.5 mL),
Et3N (125 lL, 0.9 mmol) and TBTU (96%, 130 mg, 0.40 mmol) were
added. After it completed conversion (TLC, ca. 90 min), the mixture
was concentrated under reduced pressure. Chromatography of the
residue (CHCl3/MeOH/concd NH4OH = 10:4:1 v/v/v) gave com-
pound 8 (267 mg, 86%) as a pale yellow syrup. ½a20D 7.7 (c 2.7,
MeOH); 1H NMR (500 MHz, MeOH-d4): d = 3.99 (br s, 1H, H-4),
3.87–3.76 (m, 3H, H-2, H-3, H-6a), 3.24 (dd, 1H, J = 2.5 Hz,
J = 9.1 Hz, H-6b), 3.04–2.95 (m, 3H, incl. H-1eq), 2.92 (br s 1H, H-
5), 2.88–2.77 (m, 8H), 2.77–2.67 (m, 1H, H-10a), 2.57–2.49 (m,
1H, H-10b), 2.46–2.39 (m, 1H, H-5), 2.20–2.10 (m, 3H, incl. H-
1ax), 1.65–1.55 (m, 2H), 1.55–1.45 (m, 2H), 1.34–1.20 (m, 6H),
1.15–1.01 (m, 4H); 13C NMR (125 MHz, MeOH-d4): d = 175.9 (C-
60), 77.0, 72.1, 68.8, 65.2, 62.2, 57.8 (C-1, C-2, C-3, C-4, C-5, C-6),
53.8, 45.8, 43.7, 40.1 (C-10, C-100, C-600, NMe2), 37.0 (C-50), 30.4,
30.1, 28.0, 27.2, 27.0, 26.9, 24.7. MS: Calcd for [C30H48N4O7SH]:
m/z 609.3322 [M+H]+; Found: [M+H]+ 609.3340.
3.5. N-Bis(dansylaminohexyl)aminocarbonylpentyl-1,5-
dideoxy-1,5-imino-D-galactitol (9)
To an aqueous solution (1.5 mL) of N-methoxycarbonylpentyl-
1-deoxynojirimycin (5b, 32 mg, 0.11 mmol), 0.5 M aqueous NaOH
(0.30 mL, 0.15 mmol) was added and the mixture was kept at
ambient temp for 60 min. The mixture was brought to pH 5 by
addition of aqueous HCl (5%) and the solvent was removed under
reduced pressure. Bis(6-dansylamino)hexylamine15 (B, 100 mg,
0.15 mmol) in dichloromethane (3 mL) was added to the residue
and the solvent was again removed under reduced pressure. The
residue was dissolved in DMF (1.5 mL), Et3N (30 lL, 0.22 mmol)
and TBTU (96%, 39 mg, 0.12 mmol) were added. After it completed
conversion (TLC, ca. 10 min), the mixture was concentrated under
reduced pressure and the residue was chromatographed (CHCl3/
MeOH/concd NH4OH, 50:10:1 v/v/v) providing compound 9
(90 mg, 87%) as a ﬂuorescent yellow syrup. ½a20D 6.0 (c 2.8,
MeOH); 1H NMR (500 MHz, MeOH-d4): d = 3.99 (m, 1H, H-4),
3.87–3.77 (m, 3H, H-2, H-3, H-6a), 3.64–3.57 (m, 2H), 3.24 (dd,
1H, J = 2.9 Hz, J = 9.2 Hz, H-6b), 3.10–2.97 (m, 5H, incl. H-1eq),
2.89–2.66 (m, 16H), 2.59–2.49 (m, 1H, H-10a), 2.49–2.38 (m, 1H,
H-10b), 2.27–2.11 (m, 3H, incl. H-1ax), 1.63–1.43 (m, 4H), 1.34–
1.14 (m, 14H), 1.14–1.04 (m, 4H), 1.03–0.93 (m, 4H); 13C NMR
(125 MHz, MeOH-d4): d = 174.8 (C-60), 78.3, 75.9, 71.0, 67.7, 64.0,
61.1 (C-1, C-2, C-3, C-4, C-5, C-6), 57.1, 52.7, 48.7, 46.5, 45.7, 44.8
(C-10, 2 C-100, 2 C-600, 2 NMe2), 42.6, 42.5, 32.7, 29.3, 29.2, 28.6,
27.2, 27.1, 26.1, 26.0, 25.4, 23.7. Caused by the nature of the amide
bond, some signals of carbons of the X00 sections appear at slightly
different parts per million values. MS: Calcd for [C48H72N6O9S2H]:
m/z 941.4880 [M+H]+; Found: [M+H]+ 941.4921.
3.6. N-(Dansylaminohexylamino)hexyl-3,4-O-isopropylidene-
1,5-dideoxy-1,5-imino-D-galactitol (11) and N-bis(dansylamino
hexyl)aminohexyl-3,4-O-isopropylidene-1,5-dideoxy-1,5-
imino-D-galactitol (12)
To a solution of known16 compound 10 (128 mg, 0.42 mmol)
and mesylate C15 (185 mg, 0.43 mmol) in dry N,N-dimethylform-
amide, sodium carbonate (271 mg, 2.54 mmol) was added and
the mixture was stirred at 60 C for 44 h when TLC (CHCl3/
MeOH/NH4OH concd = 12:4:1 v/v/v) indicated complete conver-
sion of the starting material. The mixture was concentrated under
reduced pressure and the remaining residue was chromatographed(CHCl3/MeOH/concd NH4OH = 40:10:1 v/v/v) to give syrupy sec-
ondary amine 11 (127 mg, 47%) and less polar tertiary amine 12
(38 mg, 9%).
Compound 11: ½a20D 3.7 (c 1.9, CH2Cl2); 1H NMR (500 MHz,
CDCl3): d = 4.27 (m, 1H, H-4), 3.91 (dd, 1H, J = 3.6 Hz, J = 11.8 Hz,
H-6a), 3.86–3.78 (m, 3H, H-2, H-3, H-6b), 2.94 (m, 1H), 2.89–2.82
(m, 8H), 2.72 (m, 1H, H-1eq), 2.64–2.46 (m, 6H), 2.08 (m, 1H, H-
1ax), 1.56–1.20 (m, 18H), 1.19–1.08 (m, 4H); 13C NMR (125 MHz,
CDCl3): d = 109.9 (isopropylidene), 81.0, 70.6, 61.8, 60.8, 54.9,
52.9 (C-1, C-2, C-3, C-4, C-5, C-6), 49.8, 49.6, 45.7, 43.4 (C-10, C-60,
C-100, C-600, NMe2), 29.7, 29.5, 29.3, 28.7, 27.5, 27.4, 26.8, 26.7,
26.4, 24.4. MS: Calcd for [C33H54N4O6SH]: m/z 635.3842 [M+H]+;
Found: [M+H]+ 635.3897.
Compound 12: ½a20D 2.8 (c 1.9, CH2Cl2); 1H NMR (500 MHz,
CDCl3): d = 4.29 (m, 1H, H-4), 3.92 (dd, 1H, J = 5.1 Hz, J = 11.9 Hz,
H-6a), 3.89–3.81 (m, 3H, H-2, H-3, H-6b), 2.96 (m, 1H, H-1eq),
2.90–2.81 (m, 16H), 2.73 (m, 1H, H-10a), 2.64 (m, 1H, H-5), 2.55
(m, 1H, H-10b), 2.32–2.21 (m, 6H), 2.18–2.07 (m, 2H, incl. H-
1ax), 1.52 (s, 3H), 1.49–1.30 (m, 12H), 1.30–1.05 (m, 14H); 13C
NMR (125 MHz, CDCl3): d = 110.1 (isopropylidene), 80.9, 77.8,
70.9, 61.7, 60.6, 54.7 (C-1, C-2, C-3, C-4, C-5, C-6), 54.0 (2 C-600),
52.9 (C-10), 45.8 (2 NMe2), 43.6 [N–(CH2–)3], 29.8, 28.6, 27.5,
27.4, 27.1, 26.8, 26.75 (3 C), 26.7 (3 C), 24.4 (2 C). MS: Calcd
for [C51H78N6O8S2H]: m/z 967.5401 [M+H]+; Found: [M+H]+
967.5460.
3.7. N-Bis(dansylaminohexyl)aminohexyl-1,5-dideoxy-1,5-
imino-D-galactitol (13)
To compound 12 (36 mg, 0.037 mmol), aqueous HCl (6%, 2 mL)
was added and the mixture was stirred at ambient temp for 3 h.
Removal of the solvent under reduced pressure provided a slightly
yellow glass which was triturated with dichloromethane and again
dried under reduced pressure to provide inhibitor 13 as the tetra-
hydrochloride (40 mg, 100%). ½a20D +2.3 (c 2.0, MeOH); 1H NMR
(500 MHz, D2O) d = 4.10 (br s, 1H, H-4), 3.87 (ddd, 1H, J1eq,2 = 5 Hz,
J1ax,2 = J2,3 = 10.6 Hz, H-2), 3.77 (m, 2H, H-6a, H-6b), 3.40 (m, 2H),
3.35–3.20 (m, 14H), 3.15–2.95 (m, 3H), 2.86–2.80 (m, 7H), 2.80–
2.55 (m, 4H), 1.70–0.38 (m, 24H). MS: Calcd for [C48H74N6O8S2H]:
m/z 927.5088 [M+H]+; Found: [M+H]+ 927.5034.
3.8. N-[(Dansylaminohexyl)-N-octanoylamino]hexyl-3,4-O-
isopropylidene-1,5-dideoxy-1,5-imino-D-galactitol (14)
To a solution of compound 11 (123 mg, 0.194 mmol) in dichlo-
romethane (6 mL) containing pyridine (25 lL, 0.31 mmol), a solu-
tion of octanoic chloride (37 lL, 0.21 mmol) in dichloromethane
(3 mL) was added at 0 C over 30 min. The reaction was then
quenched with MeOH (1 mL) and the mixture was concentrated
under reduced pressure. The residue was puriﬁed on silica gel
(CHCl3/MeOH/concd NH4OH = 150:10:1 v/v/v) to provide com-
pound 14 (105 mg, 71%) as a faintly yellow syrup. ½a20D 3.5 (c
1.4, MeOH); 1H NMR (500 MHz, CDCl3): d = 4.29 (br s, 1H, H-4),
3.92 (m, 1H, H-2), 3.88–3.81 (m, 3H, H-3, H-6a, H-6b), 3.29–3.11
(m, 3H), 3.08 (dd, 1H, J = 7.4 Hz, J = 8 Hz), 2.98 (m, 1H), 2.90–2.81
(m, 8H), 2.74 (m, 1H, H-10a), 2.63 (m, 1H, H-5), 2.54 (m, 1H, H-
10b), 2.23 (t, 1H, J = 7.5 Hz), 2.19 (t, 1H, J = 7.5 Hz), 2.08 (m, 1H,
H-1ax), 1.65–1.05 (m, 32H), 0.88–0.82 (t, 3H); 13C NMR (125
MHz, CDCl3): d = 173.2/173.1, 110.0/109.9 (isopropylidene), 81.0/
80.9, 77.8/77.7, 70.9/70.8, 61.8/61.7, 60.9/60.8, 54.7, 52.8/52.7,
48.2/48.1 (C-1, C-2, C-3, C-4, C-5, C-6, C-10, C-60), 45.9 (C-100), 45.8
(NMe3), 43.4/43.3 (C-600), 33.5/33.4, 32.1, 29.9, 29.8/29.7, 29.5,
29.2, 28.7/28.6, 27.7/27.6, 27.5/27.2, 27.0/26.9, 26.7, 26.5/26.4,
25.9/25.8, 23.0, 14.4. Due to the amide bond, double signals are ob-
served for several carbon atoms. MS: Calcd for [C41H68 N4O7SH]:m/
z 761.4887 [M+H]+; Found: [M+H]+ 761.4835.
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dideoxy-1,5-imino-D-galactitol (15)
To compound 14 (105 mg, 0.138 mmol), HCl (6% in water, 3 mL)
was added and the mixture was stirred at ambient temp for 2 h.
The solvent was removed under reduced pressure to provide inhib-
itor 15 as the di-hydrochloride (110 mg, pract. quant.) ½a20D +3.5 (c
1.25, MeOH); 1H NMR (500 MHz, D2O) d = 4.03 (m, 1H), 3.90 (m,
1H, H-2), 3.75 (m, 2H, H-6a, H-6b), 3.40 (m, 1H, H-3), 3.35–
3.3.18 (m, 6H), 3.13–2.85 (m, 6H), 2.73–2.59 (m, 3H), 2.89–2.79
(m, 2H), 2.10 (m, 1H, H-1ax), 2.00 (m, 2H), 1.60–1.43 (m, 2H),
1.37–0.67 (m, 24H), 0.83–0.75 (m, 3H); 13C NMR (125 MHz,
D2O): d = 175.1, 73.3, 70.5, 65.1, 64.7/64.6, 59.9/59.8, 54.0, 53.8,
48.7, 47.8 (2 C), 45.9, 43.2, 33.4, 32.1, 32.0, 29.7, 29.4, 29.0/29.3,
28.9, 27.6, 26.4/26.3, 26.1/26.0, 25.9/25.8, 23.0/22.9, 22.4, 14.5/
14.4. MS: Calcd for [C38H64N4O7SH]: m/z 721.4574 [M+H]+; Found:
[M+H]+ 721.4576.
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